The role of androgens in pressure overload myocardial hypertrophy

Marie Schafstedde1,2,3,4, Sarah Nordmeyer1,2,3

  • 1Department of Congenital Heart Disease - Pediatric Cardiology, Deutsches Herzzentrum der Charité - Medical Heart Center of Charité and German Heart Institute Berlin, Berlin, Germany.

Frontiers in Endocrinology
|February 23, 2023
PubMed

Insights

Androgens may contribute to left ventricular hypertrophy during pressure overload, a condition common in cardiovascular diseases. This review focuses on androgen effects specifically in pressure-induced heart muscle growth.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Cardiac Pathophysiology

Background:

  • Pressure overload leads to left ventricular hypertrophy (LVH), a key factor in cardiovascular disease progression.
  • Androgens are known for anabolic effects in skeletal muscle and have been implicated in myocardial hypertrophy.
  • Existing research often overlooks the specific role of androgens in pressure-overload-induced LVH.

Purpose of the Study:

  • To review and synthesize existing literature on the effects of androgens on left ventricular hypertrophy specifically under pressure overload conditions.
  • To differentiate androgenic influence in pressure-induced LVH from other stimuli like volume overload or general sex differences.

Main Methods:

  • Comprehensive literature search of scientific databases.
  • Inclusion criteria focused on studies examining androgens and left ventricular hypertrophy in pressure overload models.
  • Exclusion of studies on volume overload or general sex differences.

Main Results:

  • Androgens demonstrate anabolic effects on cardiac tissue, potentially exacerbating hypertrophy in response to pressure overload.
  • Evidence suggests a direct role for androgens in the structural and functional changes associated with pressure-induced LVH.
  • Specific mechanisms linking androgen signaling to cardiac myocyte growth under pressure stress are highlighted.

Conclusions:

  • Androgens play a significant role in the development of left ventricular hypertrophy under pressure overload conditions.
  • Targeting androgen pathways may offer novel therapeutic strategies for managing pressure-induced cardiac remodeling.
  • Further research is warranted to elucidate the precise molecular mechanisms involved.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
21
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
17
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
498